<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent studies have implicated the innate immunity system in the pathogenesis of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Toll-like receptor (TLR) genes encode key innate immunity signal initiators </plain></SENT>
<SENT sid="2" pm="."><plain>We recently identified multiple genes, known to be regulated by TLRs, to be overexpressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> bone marrow (BM) CD34+ cells, and hypothesized that TLR signaling is abnormally activated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed a large cohort of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases and identified that TLR1, 2 and 6 to be significantly overexpressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> BM CD34+ cells </plain></SENT>
<SENT sid="4" pm="."><plain>Deep-sequencing followed by Sanger-resequencing of TLR1, 2, 4 and 6 genes uncovered a recurrent genetic variant, TLR2-F217S, in 11% of 149 patients </plain></SENT>
<SENT sid="5" pm="."><plain>Functionally, TLR2-F217S results in enhanced activation of downstream signaling including NF-kB activity after TLR2 <z:chebi fb="4" ids="48705">agonist</z:chebi> treatment </plain></SENT>
<SENT sid="6" pm="."><plain>In cultured primary BM CD34+ cells of <z:mpath ids='MPATH_458'>normal</z:mpath> donors, TLR2 <z:chebi fb="4" ids="48705">agonists</z:chebi> induced <z:chebi fb="0" ids="15358">histone</z:chebi> demethylase JMJD3 and interleukin-8 gene expression </plain></SENT>
<SENT sid="7" pm="."><plain>Inhibition of TLR2 in BM CD34+ cells from patients with lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> using shRNA resulted in increased erythroid colony formation </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, <z:chebi fb="40" ids="33697">RNA</z:chebi> expression levels of TLR2 and 6â€‰as well as presence of TLR2-F217S are associated with distinct prognosis and clinical characteristics </plain></SENT>
<SENT sid="9" pm="."><plain>These findings indicate that TLR2-centered signaling is deregulated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and that its targeting may have potential therapeutic benefit in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>.<z:hpo ids='HP_0001909'>Leukemia</z:hpo> accepted article preview online, 14 June 2013; doi:10.1038/leu.2013.180 </plain></SENT>
</text></document>